MedPath

Effects on Recovery of Postoperative Gastrointestinal Function With Multimodal Analgesia

Not Applicable
Not yet recruiting
Conditions
Gastrointestinal Recovery
Interventions
Drug: Placebo
Registration Number
NCT04314310
Lead Sponsor
National Taiwan University Hospital
Brief Summary

breast cancer surgery is associated with a high incidence of persistant postsurgical pain (PPSP). The aim of the study was to evluate the impact of intravenous Tenoxicam on acute and PPSP, analgesic requirements and gastrointestinal recovery in patients undergoing surgery for breast cancer.

Detailed Description

thrity patients participated in this randomized, single-blined study. Before and at the postoperative day 1, the bowel function (orocecal transmit time) were measured. Before induction of general anesthesia, patients recieved a bolus of intravenous Tenoxicam or an equal volume of saline (control group). Pain score and opioid consumption were recorded in the postoperative period and then daily for 1 week.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
Female
Target Recruitment
30
Inclusion Criteria
  • ASA I to II Breast cancer patients Mastectomy or wide local excision + axillary note dissection
Exclusion Criteria
  • Preexisting malignancy Chronic infection Previous pain condition Diabetes Thyroid disorder Severe cardiac, renal or hepatic disease Previous breast surgery Psychiatric illness Neurological disease Contraindication for tenoxicam or morphine use

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
placeboPlaceboequal volume of normal saline
TenoxicamTenoxicamnonsteroidal anti-inflammatory drug (NSAID)
Primary Outcome Measures
NameTimeMethod
morphine consumptionuntil postoperative day7

morphine consumption after breast cancer surgery

Secondary Outcome Measures
NameTimeMethod
orocecal transmit time,preoperative and postoperative day 1

smal intestinal function

© Copyright 2025. All Rights Reserved by MedPath